Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma

Jonathon B. Cohen, MD, Jeffrey Switchenko, PhD, Jean L. Koff, MD, Rajni Sinha, MD MRCP, Jonathan L. Kaufman, MD, H. Jean Khoury, MD FACP, Nassoma K Bumpers, PA, Amanda Colbert, Amanda A Hutchison-Rzepka, BA, Loretta J. Nastoupil, MD, Leonard T. Heffner, MD, Amelia Langston, MD, Mary Jo Lechowicz, MD, Sagar Lonial, MD, Christopher R. Flowers, MD

Blood (2014) 124 (21): 4432.

https://doi.org/10.1182/blood.V124.21.4432.4432

Published: 2014

Journal Articles

Racial Disparities in Cell of Origin Among DLBCL Patients.

Christopher R. Flowers, MD, Loretta Nastoupil, MD, Uma Borate, MD, MS, Pareen J Shenoy, MBBS, MPH, Will Donnellan, Nassoma King, PA, Kevin Bumpers, MHA, Mary Jo Lechowicz, MD, Leon Bernal-Mizrachi, M.D., Rajni Sinha, MD, MRCP, Elizabeth Chastain, MD, Kevin E Fisher, M.D., Ph.D., James M. Foran, MD, FRCPC, Vishnu Reddy, MD, David L Jaye, MD

Blood (2012) 120 (21): 2686.

https://doi.org/10.1182/blood.V120.21.2686.2686

Published: 2012

Journal Articles

GM-CSF and IL-4 Derived Fusion Cytokine Reprograms Leukemic B-Cells to Anti-CLL Effectors

Jiusheng Deng, PhD, Andrea Pennati, PhD, Pingxin Li, PhD, Shala Yuan, MSc, Jordan Murphy, BS, Spencer Ng, BSc, Rajni Sinha, MD, MRCP, Christopher R. Flowers, MD, Jacques Galipeau, MD

Blood (2012) 120 (21): 4606.

https://doi.org/10.1182/blood.V120.21.4606.4606

Published: 2012

Journal Articles

Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma

Loretta Nastoupil, MD, Pareen J Shenoy, MBBS, MPH, Alex Ambinder, Miray Seward, Ajay K. Nooka, MD, MPH, FACP, Edmund K. Waller, MD, PhD, Amelia Langston, MD, Jonathan L. Kaufman, MD, Nassoma King, PA, Mary Jo Lechowicz, MD, Sagar Lonial, MD, Rajni Sinha, MD, MRCP, Christopher R. Flowers, MD

Blood (2012) 120 (21): 2006.

https://doi.org/10.1182/blood.V120.21.2006.2006

Published: 2012

Journal Articles

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Andre Goy, MD, Rajni Sinha, MD, MRCP, Michael E. Williams, M.D., Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M. Rowe, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, MD, PhD, Lei Zhang, MD, Sherri Cicero, Tommy Fu, Thomas E. Witzig, MD

Blood (2012) 120 (21): 905.

https://doi.org/10.1182/blood.V120.21.905.905

Published: 2012

Journal Articles

Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis

J. Mark Prichard, MD, Samatha Muppidi, MD, Christopher R Flowers, MD, Jonathan L. Kaufman, MD, Mary Jo Lechowicz, MD, Sagar Lonial, MD, Ajay K. Nooka, MD, MPH, FACP, Rajni Sinha, MD, MRCP, Edmund K Waller, MD, PhD, Amelia Langston, MD

Blood (2011) 118 (21): 1959.

https://doi.org/10.1182/blood.V118.21.1959.1959

Published: 2011

Journal Articles

A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States

Loretta Nastoupil, MD, Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Brian K Link, MD, Ryan M Ziemiecki, MS, Jamie H. Hirata, PharmD, Christopher R Flowers, MD

Blood (2011) 118 (21): 97.

https://doi.org/10.1182/blood.V118.21.97.97

Published: 2011

Journal Articles

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Nutan J. DeJoubner, MD, Ajay K. Nooka, MD, MPH, FACP, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Ryan M Ziemiecki, MS, Jamie H. Hirata, PharmD, Brian K Link, MD, Christopher R Flowers, MD

Blood (2011) 118 (21): 775.

https://doi.org/10.1182/blood.V118.21.775.775

Published: 2011

Journal Articles

Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004–2007,

Loretta Nastoupil, MD, Rajni Sinha, MD, MRCP, Michelle Byrtek, PhD, Xiaolei Zhou, Michael Taylor, PharmD, PhD, James R Cerhan, MD, PhD, Jonathan Friedberg, MD, Brian K Link, MD, Jamie H. Hirata, PharmD, Christopher R Flowers, MD

Blood (2011) 118 (21): 3708.

https://doi.org/10.1182/blood.V118.21.3708.3708

Published: 2011

Journal Articles

Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial

R. Donald Harvey, PharmD, Sagar Lonial, MD, Heather Renfroe, Rajni Sinha, MD, MRCP, Christopher R Flowers, MD, Mary Jo Lechowicz, MD, H. Jean Khoury, MD, FACP, Amelia Langston, MD, Edmund K Waller, MD PhD, Jonathan L. Kaufman, MD

Blood (2011) 118 (21): 2988.

https://doi.org/10.1182/blood.V118.21.2988.2988

Published: 2011

Journal Articles

Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)

Rajni Sinha, MD, MRCP, Nassoma King, PA, Pareen J Shenoy, MBBS, MPH, Mary Jo Lechowicz, MD, Kevin Bumpers, MHA, Donald Hutcherson, Martha Arellano, MD, Amelia Langston, MD, Jonathan L. Kaufman, MD, Leonard T. Heffner, MD, Edmund K Waller, MD PhD, Christopher R Flowers, MD, Sagar Lonial, MD

Blood (2011) 118 (21): 1628.

https://doi.org/10.1182/blood.V118.21.1628.1628

Published: 2011

Journal Articles

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff Sharman, John Sweetenham, Patrick B. Johnston, Julie M. Vose, Ann LaCasce, Julia Schaefer-Cutillo, Sven De Vos, Rajni Sinha, John P. Leonard, Larry D. Cripe, Stephanie A. Gregory, Michael P. Sterba, Ann M. Lowe, Ronald Levy, Margaret A. Shipp

Blood (2010) 115 (13): 2578–2585.

https://doi.org/10.1182/blood-2009-08-236471

Published: 2010

Journal Articles

The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.

Deshpande S. Deshpande, PhD, Mary Jo Lechowicz, MD, Rajni Sinha, MD, MRCP, Jonathan L. Kaufman, MD, Lawrence H. Boise, PhD, Sagar Lonial, MD, Christopher R. Flowers, MD

Blood (2009) 114 (22): 1689.

https://doi.org/10.1182/blood.V114.22.1689.1689

Published: 2009

Journal Articles

Black/White Differences in the Treatment and Outcomes of Diffuse Large B Cell Lymphoma: A Matched Cohort Analysis.

Pareen J. Shenoy, MBBS, MPH, Kevin Bumpers, MPA, Nassoma King, PA, Taoying Huang, MS, Neha Malik, Rajni Sinha, MD, MRCP, Christopher R. Flowers, MD

Blood (2009) 114 (22): 1392.

https://doi.org/10.1182/blood.V114.22.1392.1392

Published: 2009

Journal Articles

Racial Differences in the Presentation and Outcomes of Diffuse Large B-Cell Lymphoma in the United States.

Neha Malik, Pareen J. Shenoy, MBBS, MPH, Kevin Bumpers, MPA, Rajni Sinha, MD, MRCP, Christopher R. Flowers, MD

Blood (2009) 114 (22): 898.

https://doi.org/10.1182/blood.V114.22.898.898

Published: 2009

Journal Articles

Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

Disni Muringampurath-John, MBBS, Christopher R. Flowers, MD, Adnan A Jabbar, MD, PhD, Rajni Sinha, MD, MRCP, Martha Arellano, MD, Leon Bernal-Mizrachi, MD, Jonathan L. Kaufman, MD, David L. Jaye, MD, Zhengjia Chen, Mary Jo Lechowicz, MD, Sagar Lonial, MD, James O. Armitage, M.D., H. Jean Khoury, MD

Blood (2009) 114 (22): 2947.

https://doi.org/10.1182/blood.V114.22.2947.2947

Published: 2009

Journal Articles

Imatinib Mesylate and Hyper-CVAD (IM-HCVAD) for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

Martha Arellano, MD, Disni Muringampurath-John, MD, Pareen J. Shenoy, MBBS, MPH, Elliott F. Winton, MD, Beverly Bryan, Amelia Langston, MD, Rajni Sinha, MD, MRCP, Morgan L. McLemore, MD, Leonard Heffner, MD, H. Jean Khoury, MD

Blood (2009) 114 (22): 4103.

https://doi.org/10.1182/blood.V114.22.4103.4103

Published: 2009

Journal Articles

The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated.

Rajni Sinha, MD, MRCP, Jonathan L. Kaufman, MD, Hanna Jean Khoury, Jr., MD, Nassoma King, PA, Pareen J. Shenoy, MBBS, MPH, Carol Lewis, Kevin Bumpers, MPA, Sagar Lonial, MD, Christopher R. Flowers, MD

Blood (2009) 114 (22): 3718.

https://doi.org/10.1182/blood.V114.22.3718.3718

Published: 2009

Journal Articles

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Jonathan W. Friedberg, MD, Jeff Sharman, Julia Schaefer-Cutillo, Patrick B. Johnston, Sven De Vos, MD, PhD, Ann LaCasce, MD, John P. Leonard, MD, Larry D. Cripe, MD, Rajni Sinha, MD, Stephanie A. Gregory, John Sweetenham, Julie M. Vose, MD, Ann M Lowe, MD, R. Levy, Margaret A. Shipp, MD

Blood (2008) 112 (11): 3.

https://doi.org/10.1182/blood.V112.11.3.3

Published: 2008

Journal Articles

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

Amelia A Langston, MD, Sujatha Murali, MD, Stephanie McMillan, RN, Leonard T. Heffner, MD, Sagar Lonial, MD, Edmund K. Waller, MD, PhD, Christopher R. Flowers, MD, Jonathan Kaufman, MD, Morgan L. McLemore, MD, Rajni Sinha, MD, Mary J Lechowicz, MD, H. Jean Khoury, MD, Elliott F. Winton, MD

Blood (2008) 112 (11): 3644.

https://doi.org/10.1182/blood.V112.11.3644.3644

Published: 2008

NARROW

A Phase II Trial of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent Non-Hodgkin’s Lymphoma

Racial Disparities in Cell of Origin Among DLBCL Patients.

GM-CSF and IL-4 Derived Fusion Cytokine Reprograms Leukemic B-Cells to Anti-CLL Effectors

Consolidation with High Dose Therapy and Autologous Stem Cell Transplant Improves Survival for Patients with Mantle Cell Lymphoma

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis

A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States

Examining the Outcomes of Watchful Waiting (WW) Among US Patients with Advanced Stage Follicular Lymphoma (FL)

Characteristics and Effectiveness of Rituximab (R) Maintenance Regimens Among US Patients Diagnosed with Follicular Lymphoma (FL) 2004–2007,

Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial

Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.

Black/White Differences in the Treatment and Outcomes of Diffuse Large B Cell Lymphoma: A Matched Cohort Analysis.

Racial Differences in the Presentation and Outcomes of Diffuse Large B-Cell Lymphoma in the United States.

Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL).

Imatinib Mesylate and Hyper-CVAD (IM-HCVAD) for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL).

The Addition of Bortezomib to Modified R-CHOP as Initial Therapy for Follicular NHL Results in High CR Rate and Is Well Tolerated.

Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL)

Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only